Citations

Clear

1446 citation(s) found for "Howard, F".

Surgical Management and Reconstruction of Hoffman’s Disease (Dissecting Cellulitis of the Scalp)
Hintze, Justin M. , Howard, Brittany E. , Donald, Carrlene B., Hayden, Richard E. , Hintze, Justin

Mayo Clinic

Case Reports in Surgery | February 7, 2016 | Volume: 2016 | Issue: No issue available | Pages: 1-4

10.1155/2016/2123037 | PMID 26966606 Get It

Dissecting cellulitis of the scalp, or Hoffman’s disease, is a rare dermatologic condition characterized by recurrent pustules and sinus tract formation leading to scarring and alopecia. Medical management includes the use of corticosteroids, antibiotics, isotretinoin, and adalimumab. In cases where the disease is severe, refractory, and intractable, surgery is an option. We report two cases of Hoffman’s disease, where medical management failed to achieve remission. Surgical treatment was undertaken with complete resection of the affected scalp in staged procedures with subsequent split-thickness skin grafting for reconstruction. Surgery achieved both disease remission and excellent aesthetic outcomes in both patients.
Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors
Hoff, Daniel D. Von , Mita, Monica , Ramanathan, Ramesh K., Mita, Alain C. , LoRusso, Patricia , Burris, Howard A. , Hart, Lowell L., Low, Susan C. , Parsons, Donald M., Zale, Stephen E., Summa, Jason M., Youssoufian, Hagop , Sachdev, Jasgit C. , Weiss, Glen J.

Mayo Clinic

Clinical Cancer Research | February 4, 2016 | Volume: 22 | Issue: 13 | Pages: 3157-3163

10.1158/1078-0432.ccr-15-2548 | PMID 26847057 Get It

Abstract Purpose: First-in-human phase I trial to determine the safety, pharmacokinetics, and antitumor activity of BIND-014, a novel, tumor prostate-specific membrane antigen (PSMA)–targeted nanoparticle, containing docetaxel. Experimental Design: Patients with advanced solid tumors received BIND-014 every three weeks (n = 28) or weekly (n = 27), with dose levels ranging from 3.5 to 75 mg/m2 and 15 to 45 mg/m2, respectively. Results: BIND-014 was generally well tolerated, with no unexpected toxicities. The most common drug-related toxicities (>20% of patients) on either schedule included neutropenia, fatigue, anemia, alopecia, and diarrhea. BIND-014 demonstrated a dose-linear pharmacokinetic profile, distinct from docetaxel, with prolonged persistence of docetaxel-encapsulated circulating nanoparticles. Of the 52 patients evaluable for response, one had a complete response (cervical cancer on the every three week schedule) and five had partial responses (ampullary adenocarcinoma, non–small cell lung, and prostate cancers on the every-three-week schedule, and breast and gastroesophageal cancers on the weekly schedule). Responses were noted in both PSMA-detectable and -undetectable tumors. Conclusions: BIND-014 was generally well tolerated, with predictable and manageable toxicity and a unique pharmacokinetic profile compared with conventional docetaxel. Clinical activity was noted in multiple tumor types. The recommended phase II dose of BIND-014 is 60 mg/m2 every three weeks or 40 mg/m2 weekly. Clin Cancer Res; 22(13); 3157–63. ©2016 AACR.
Lymphocytic variant of hypereosinophilic syndrome mimicking peripheral T-cell lymphoma in a young woman
King, Rebecca L. , Howard, Matthew T.

Mayo Clinic

Blood | January 15, 2016 | Volume: 127 | Issue: 2 | Pages: 268-268

10.1182/blood-2015-10-674945 | PMID 28837310 Get It

Validation of a bone scan positivity risk table in non‐metastatic castration‐resistant prostate cancer
Freedland, Stephen J. , Howard, Lauren E. , Hanyok, Brian T. , Kadiyala, Vishnu , Kuang, Jameson, Whitney, Colette , Wilks, Floyd , Amling, Christopher L. , Moreira, Daniel M. , Kane, Christopher J. , Terris, Martha K. , Cooperberg, Matthew R , Aronson, William J. , Howard, Lauren E

Mayo Clinic

BJU International | January 13, 2016 | Volume: 118 | Issue: 4 | Pages: 570-577

10.1111/bju.13405 | PMID 26762961 Get It

Objectives To test the external validity of a previously developed risk table, designed to predict the probability of a positive bone scan among men with non‐metastatic (M0) castration‐resistant prostate cancer ( CRPC ), in a separate cohort. Patients and Methods We retrospectively analysed 429 bone scans of 281 patients with CRPC , with no known previous metastases, treated at three Veterans Affairs Medical Centers. We assessed the predictors of a positive scan using generalized estimating equations. Area under the curve ( AUC ), calibration plots and decision‐curve analysis were used to assess the performance of our previous model to predict a positive scan in the current data. Results A total of 113 scans (26%) were positive. On multivariable analysis, the only significant predictors of a positive scan were log‐transformed prostate‐specific antigen ( PSA ): hazard ratio ( HR ) 2.13; 95% confidence interval ( CI ) 1.71–2.66 ( P < 0.001) and log‐transformed PSA doubling time ( PSADT ): HR 0.53; 95% CI 0.41–0.68 ( P < 0.001). Among men with a PSA level <5 ng/ mL , the rate of positive scans was 5%. The previously developed risk table had an AUC of 0.735 to predict positive bone scan with excellent calibration, and provided additional net benefit in the decision‐curve analysis. Conclusion We have validated our previously developed table to predict the risk of a positive bone scan among men with M0/Mx CRPC . Use of this risk table may allow better tailoring of patients' scanning to identify metastases early, while minimizing over‐imaging. Regardless of PSADT , positive bone scans were rare in men with a PSA <5 ng/ mL .
P3‐309: Advancing research and treatment of frontotemporal lobar degeneration (ARTFL): Preparing for clinical trials for ftld in north america
Boxer, Adam L. , Rosen, Howard J. , Bordelon, Yvette , Coppola, Giovanni , Dickerson, Brad C., Ghoshal, Nupur , Graff-Radford, N. R., Huey, Edward D. , Kaufer, Daniel , Kornak, John , Mackenzie, Ian R. , Mendez, Mario F. , Onyike, Chiadi U. , Rademakers, Rosa , Weıntraub, Sandra , Boeve, Bradley F. , Grossman, Murray , Hsiung, Ging‐Yuek Robin , Irwin, David J. , Litvan, Irene , Knopman, David S. , Miller, Bruce L. , Tartaglia, Maria Carmela

Mayo Clinic

Alzheimer's & Dementia | December 15, 2015 | Volume: 11 | Issue: 7S_Part_16 | Pages: No page available

10.1016/j.jalz.2015.06.1683 Get It

O5‐03‐01: Longitudinal evaluation of familial frontotemporal dementia subjects (LEFFTDS): Subject characteristics, aims, and methodology
Rosen, Howard J. , Boxer, Adam L. , Dickerson, Brad C., Ghoshal, Nupur , Graff‐Radford, Neill R. , Huey, Edward D. , Kornak, John , Mackenzie, Ian R. , Petrucelli, Leonard , Rademakers, Rosa , Shaw, Leslie M. , Trojanowski, John Q. , Boeve, Bradley F. , Feldman, Howard , Goldman, Jill , Grossman, Murray , Hsiung, Ging‐Yuek Robin , Irwin, David J. , Jack, Clifford R. , Kantarci, Kejal , Knopman, David S. , Miller, Bruce L. , Toga, Arthur W. , Wszołek, Zbigniew K.

Mayo Clinic

Alzheimer's & Dementia | December 15, 2015 | Volume: 11 | Issue: 7S_Part_7 | Pages: No page available

10.1016/j.jalz.2015.07.457 Get It

Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine
Burns, Ted M., Smith, Gordon, Allen, Jeffrey A. , Amato, Anthony A. , Arnold, W. David , Barohn, Richard J., Benatar, Michael , Bird, Shawn J. , Bromberg, Mark B. , Chahin, Nizar, Ciafaloni, Emma , Corse, Andrea M. , David, William S., Dimberg, Elliot L., Sousa, De , Donofrio, Peter D., Dyck, P. James B. , Engel, Andrew G. , Ensrud, Erik , Ferrante, Mark A., Freimer, Miriam , Gable, Karissa , Gibson, Summer, Gilchrist, James M. , Goldstein, Jonathan , Gooch, Clifton L. , Goodman, Brent P., Gorelov, Dmitri, Gospe, Sídney M. , Goyal, Namita , Guidon, Amanda C. , Guptill, Jeffrey T. , Gutmann, Laurie , Gutmann, Ludwig , Gwathmey, Kelly , Harati, Yadollah, Harper, C. Michel , Hehir, Michael K. , Hobson‐Webb, Lisa D., Howard, James F. , Jackson, Carlayne E. , Jones, Sarah , Juel, Vern C. , Kaminski, Henry J. , Kennelly, Kathleen D., Khella, Sami, Khoury, Julie, Kincaid, John C., Kissel, John T., Kolb, Noah , Lacomis, David , Larriviere, Daniel G., Lewis, Richard A. , Litchy, William J. , Logigian, Eric L. , Lou, Jau-Shin, MacGowen, Daniel J.L., Maselli, Ricardo A. , Massey, Janice M., Mauermann, Michelle L. , Mathews, Katherine D. , Meriggioli, Matthew N. , Moon, Joon-Shik, Mozaffar, Tahseen , Nations, Sharon , Ostrow, Lyle W. , Pascuzzi, Robert M. , Peltier, Amanda , Ruzhansky, Katherine , Ross, Mark A., Rubin, Devon I., Russell, James A., Sachs, George, Salajegheh, Mohammad, Saperstein, David , Scelsa, Stephen N. , Selcen, Duygu , Shaibani, Aziz , Silvestri, Nicholas J. , Singleton, J. Rob, Smith, Benn E., So, Yuen T., Solórzano, Guillermo, Sorenson, Eric J. , Srinivasen, Jayashri, Tavee, Jinny , Tawil, Rabi , Thaisetthawatkul, Pariwat , Thornton, Charles A. , Trivedi, Jaya , Vernino, Steven , Wang, Annabel K., Webb, Tyler A., Weiss, Michael D. , Windebank, Anthony J. , Wolfe, Gil I. , Crum, Brian A. , Dimberg, Elliot, Chahin, Nizar, Cohen, Jeffrey Allen , Johnson, Nicholas E , Karam, Chafic , Ladha, Shafeeq , Li, Yuebing , Miller, Robert G. , Nowak, Richard J. , Richman, David P. , Shieh, Perry B. , Kolb, Noah A , Mauermann, Michelle L , Gutmann, Laurie , Allen, Jeffrey A , Arnold, W David , Vernino, Steven , Kaminski, Henry

Mayo Clinic

Muscle & Nerve | December 13, 2015 | Volume: 53 | Issue: 2 | Pages: 165-168

10.1002/mus.25009 | PMID 26662952 Get It

Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer
Roberts, Nicholas J. , Norris, Alexis L. , Petersen, Gloria M. , Bondy, Melissa L. , Gallinger, Steven , Kurtz, Robert C. , Olson, Sara H. , Rustgi, Anil K. , Schwartz, Ann G. , Zogopoulos, George , Ali, Syed Z. , Axilbund, Jennifer E., Chaffee, Kari G. , Childs, Erica J., Herman, Joseph M. , Kramer, Melissa , Makohon-Moore, Alvin P. , McCombie, W. Richard , McMahon, K. Wyatt, Niknafs, Noushin , Parla, Jennifer, Pirooznia, Mehdi , Potash, James B. , Rhim, Andrew D. , Smith, Alyssa , Wolfgang, Christopher L. , Wood, Laura D. , Zandi, Peter P. , Karchin, Rachel , Eshleman, James R. , Papadopoulos, Nickolas , Kinzler, Kenneth W. , Vogelstein, Bert , Hruban, Ralph H. , Rabe, Kari G. , Brand, Randall E. , Stoffel, Elena M. , Syngal, Sapna , Chen, Yunching , Coté, Michele L. , Douville, Christopher , Goes, Fernando , Iacobuzio–Donahue, Christine A. , Wang, Yuxuan , Goggins, Michael , Klein, Alison P. , Pirooznia, Mehdi

Mayo Clinic

Cancer Discovery | December 9, 2015 | Volume: 6 | Issue: 2 | Pages: 166-175

10.1158/2159-8290.cd-15-0402 | PMID 26658419 Get It

Abstract Pancreatic cancer is projected to become the second leading cause of cancer-related death in the United States by 2020. A familial aggregation of pancreatic cancer has been established, but the cause of this aggregation in most families is unknown. To determine the genetic basis of susceptibility in these families, we sequenced the germline genomes of 638 patients with familial pancreatic cancer and the tumor exomes of 39 familial pancreatic adenocarcinomas. Our analyses support the role of previously identified familial pancreatic cancer susceptibility genes such as BRCA2, CDKN2A, and ATM, and identify novel candidate genes harboring rare, deleterious germline variants for further characterization. We also show how somatic point mutations that occur during hematopoiesis can affect the interpretation of genome-wide studies of hereditary traits. Our observations have important implications for the etiology of pancreatic cancer and for the identification of susceptibility genes in other common cancer types. Significance: The genetic basis of disease susceptibility in the majority of patients with familial pancreatic cancer is unknown. We whole genome sequenced 638 patients with familial pancreatic cancer and demonstrate that the genetic underpinning of inherited pancreatic cancer is highly heterogeneous. This has significant implications for the management of patients with familial pancreatic cancer. Cancer Discov; 6(2); 166–75. ©2015 AACR. This article is highlighted in the In This Issue feature, p. 109
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
Basch, Ethan , Deal, Allison M. , Scher, Howard I. , Hudis, Clifford A. , Sabbatini, Paul , Rogak, Lauren J. , Dueck, Amylou C. , Atkinson, Thomas M. , Chou, Joanne F. , Dulko, Dorothy , Sit, Laura , Leahy, Allison Barz , Novotny, Paul J. , Fruscione, M. , Sloan, Jeff A. , Schrag, Deborah , Kris, Mark G, Rogak, Lauren , Bennett, Antonia V. , Barz, Allison, Novotny, Paul, Fruscione, Michael, Dueck, A. C. , Basch, Ethan , Deal, Allison , Kris, Mark G. , Bennett, Antonia V , Schrag, Deborah , Leahy, Allison B

Mayo Clinic

Journal of Clinical Oncology | December 8, 2015 | Volume: 34 | Issue: 6 | Pages: 557-565

10.1200/jco.2015.63.0830 | PMID 26644527 Get It

Purpose There is growing interest to enhance symptom monitoring during routine cancer care using patient-reported outcomes, but evidence of impact on clinical outcomes is limited. Methods We randomly assigned patients receiving routine outpatient chemotherapy for advanced solid tumors at Memorial Sloan Kettering Cancer Center to report 12 common symptoms via tablet computers or to receive usual care consisting of symptom monitoring at the discretion of clinicians. Those with home computers received weekly e-mail prompts to report between visits. Treating physicians received symptom printouts at visits, and nurses received e-mail alerts when participants reported severe or worsening symptoms. The primary outcome was change in health-related quality of life (HRQL) at 6 months compared with baseline, measured by the EuroQol EQ-5D Index. Secondary endpoints included emergency room (ER) visits, hospitalizations, and survival. Results Among 766 patients allocated, HRQL improved among more participants in the intervention group than usual care (34% v 18%) and worsened among fewer (38% v 53%; P < .001). Overall, mean HRQL declined by less in the intervention group than usual care (1.4- v 7.1-point drop; P < .001). Patients receiving intervention were less frequently admitted to the ER (34% v 41%; P = .02) or hospitalized (45% v 49%; P = .08) and remained on chemotherapy longer (mean, 8.2 v 6.3 months; P = .002). Although 75% of the intervention group was alive at 1 year, 69% with usual care survived the year (P = .05), with differences also seen in quality-adjusted survival (mean of 8.7 v. 8.0 months; P = .004). Benefits were greater for participants lacking prior computer experience. Most patients receiving intervention (63%) reported severe symptoms during the study. Nurses frequently initiated clinical actions in response to e-mail alerts. Conclusion Clinical benefits were associated with symptom self-reporting during cancer care.
Acoustic Neuromas with Normal Pure Tone Hearing Levels
Beck, Howard J., Beatty, Charles W., Harner, Stephen G., Ilstrup, Duane M.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | November 25, 2015 | Volume: 94 | Issue: 1 | Pages: 96-103

10.1177/019459988609400116 | PMID 3081864 Get It

From 1966 through 1983, 408 patients underwent primary removal of an acoustic neuroma at the Mayo Clinic. Of these, 21 had preoperative pure tone hearing levels of 25 dB hearing loss or better at 500, 1000, and 2000 Hz, which for this study was defined as normal pure tone hearing. Fourteen patients (67%) had dysequilibrium and 13 (62%) had subjective hearing impairment. Nystagmus was the most common physical finding. Five patients (23%) had completely symmetric pure tone hearing levels through all frequencies tested. The mean speech discrimination score was 90%. Mean tumor size was 2.4 cm. Brain stem evoked response audiometry was the most helpful of the special tests in the evaluation of these patients with normal pure tone hearing levels. Our results suggest that 5% of patients with acoustic neuromas have normal pure tone hearing levels. A careful history, a thorough physical examination, and an appropriate selection of tests will identify these patients.